Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations

Eleje, George Uchenna; Eke, Ahizechukwu C.; Ezebialu, Ifeanyichukwu U.; Ikechebelu, Joseph Ifeanyichukwu; Ugwu, Emmanuel Onyebuchi; Okonkwo, Onyinye O

doi:10.1002/14651858.cd012464.pub2

Cited by 100 publications

(95 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A prospective observational study showed that oophorectomy or salpingo-oophorectomy reduced the risk of OC by 80% [39]. A Cochrane meta-analysis including ten cohort studies and 8087 BRCA m carriers concluded with very-low certainty evidence that risk-reducing sapingo-oophorectomy reduces risk of death from OC [40]. A large cohort study found reduced risk of OC with tubal-ligation in BRCA 1/2 mutation carriers (HR, 0.43; 95% CI, 0.24–0.75; p = 0.003) [41].…”

Section: Introductionmentioning

confidence: 99%

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

Madariaga

Lheureux

Oza

2019

Cancers

View full text Add to dashboard Cite

High grade serous ovarian cancer (HGSOC) is the most common epithelial ovarian cancer, harbouring more than 20% germline or somatic mutations in the tumour suppressor genes BRCA1 and BRCA2. These genes are involved in both DNA damage repair process via homologous recombination (HR) and transcriptional regulation. BRCA mutation confers distinct characteristics, including an increased response to DNA-damaging agents, such us platinum chemotherapy and poly-ADP ribose polymerase inhibitors (PARPi). However, several mechanisms of resistance to these agents have been described, including increased HR capacity through reverse BRCA mutations, non-homologous end-joint (NHEJ) repair alterations and drug efflux pumps. Current treatments of ovarian cancer including surgery, chemotherapy, targeted treatment and maintenance strategies, as well as resistance mechanisms will be reviewed, focusing on future trends with respect to BRCA mutation carriers.

show abstract

Section: Introductionmentioning

confidence: 99%

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

Madariaga

Lheureux

Oza

2019

Cancers

View full text Add to dashboard Cite

show abstract

“…This difference may be the result of a “counselled risk”, based on the lower incidence and the slightly better prognosis of ovarian cancer in BRCA2 mutation carriers. However, a recent Cochrane review shows that BRCA carriers who received RRSO had longer overall survival, lower BC and OC mortality and better quality of life in term of OC risk perception [30]. Meta-analyses showed that RRSO might reduce the risk of death from OC and BC in BRCA1 carriers, but its role in BRCA2 carriers was uncertain.…”

Section: Discussionmentioning

confidence: 99%

Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome

Modaffari

Ponzone

Ferrari

et al. 2019

JCM

View full text Add to dashboard Cite

Hereditary Breast and Ovarian Cancer syndrome (HBOC) carriers face complex decisions, which might affect their fertility and body image. Using an anonymous 40-items questionnaire we evaluated the expectations and concerns about Risk-Reducing Surgery (RRS) in 204 carriers. Participants are well-informed about the options to manage cancer risk, and women with previous cancer are more concerned with screening failure. Satisfaction with RR Mastectomy is high, even if many carriers are unsatisfied with reconstructed breast feel and nipple-areola complex tactile sensation and those with previous breast cancer report a change in their sexual habits. The decrease of libido and vaginal dryness are the most complained symptoms after RR Salpingo-Oophorectomy. Nevertheless, most carriers would choose RRS again, due to cancer risk or screening-related stress reduction. Women who deferred RRS are more afraid of menopausal symptoms and cancer risk than those who had undergone or declined surgery. Women who declined RRS feel well-informed and trust screening procedures. In conclusion, HBOC carriers consider themselves well-informed and able to choose the best option for their condition, would choose RRS again because of cancer risk and screening-related stress reduction, and those who delay RRS face a higher preoperative level of concern and need support.

show abstract

“…Current guidelines suggest that the assessment for cancer predisposition should be warranted only to those patients who are likely to have an inherited mutation, mainly based on personal or family history of BC or OR 11 , 17 .…”

Section: Introductionmentioning

confidence: 99%

Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study)

Nero

Ciccarone

Boldrini

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Radiogenomics is a specific application of radiomics where imaging features are linked to genomic profiles. We aim to develop a radiogenomics model based on ovarian US images for predicting germline BRCA1/2 gene status in women with healthy ovaries. From January 2013 to December 2017 a total of 255 patients addressed to germline BRCA1/2 testing and pelvic US documenting normal ovaries, were retrospectively included. Feature selection for univariate analysis was carried out via correlation analysis. Multivariable analysis for classification of germline BRCA1/2 status was then carried out via logistic regression, support vector machine, ensemble of decision trees and automated machine learning pipelines. Data were split into a training (75%) and a testing (25%) set. The four strategies obtained a similar performance in terms of accuracy on the testing set (from 0.54 of logistic regression to 0.64 of the auto-machine learning pipeline). Data coming from one of the tested US machine showed generally higher performances, particularly with the auto-machine learning pipeline (testing set specificity 0.87, negative predictive value 0.73, accuracy value 0.72 and 0.79 on training set). The study shows that a radiogenomics model on machine learning techniques is feasible and potentially useful for predicting gBRCA1/2 status in women with healthy ovaries.

show abstract

Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations

Cited by 100 publications

References 151 publications

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome

Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study)

Contact Info

Product

Resources

About